![]() Brain and lesion volumes measured using image segmentation have become established biomarkers for determining treatment efficacy in research studies and clinical trials. MRI-based measurement of brain atrophy is becoming increasingly recognized as an important clinical prognostication tool. Structural MRI is routinely used in the diagnostic workup of MS and to assess and monitor demyelinating lesions. Both lesion evolution and brain volume loss over time correlate with clinical disability. Brain atrophy is accelerated in MS compared to the healthy population. Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system characterized by demyelinating lesions and atrophy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |